P1.12 * A Phase I Dose Defining Study for MK-2206 Combined...

Annals of Oncology 2015 / 03 Vol. 26; Iss. suppl 2

P1.12 * A Phase I Dose Defining Study for MK-2206 Combined with Gefitinib in NSCLC Population Enriched with EGFR Mutation

Lin, C.- C., Yu, C.- J., Ho, C.- C., Chen, K.- Y., Shih, J.- Y., Lin, Z.- Z., Lin, Y.- L., Liao, W.- Y., Tsai, S.- H., Yan, L., Yang, J. C.- H.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv090.12
Date:
March, 2015
File:
PDF, 30 KB
english, 2015
Conversion to is in progress
Conversion to is failed